4583 Chiome Bioscience
- 109
- -1-0.91%
Chiome Bioscience News
Chiome Bioscience: Announcements of the exercise of large amounts of subscription rights (with exercise price adjustment clause) in the 21st period.
Chiome Bioscience: Report on Corporate Governance, August 14, 2024.
Chiome Bioscience: Confirmation letter
Chiome Bioscience: Interim Report - 21st period (01/01/2024 - 12/31/2024)
Chiome Bioscience: Supplementary information on the financial results for the second quarter of the period ending December 2024.
Chiome Bioscience: Non-consolidated performance for the 6 months ending on June 30th, 2024 (Japanese accounting standards).
Chiome Bioscience: Supplementary financial data for the second quarter of the 2024 fiscal year ending in December.
Chiome Bioscience: Financial results report for the second quarter (interim period) of December 2024, based on Japanese standards (non-consolidated).
Chiome Bioscience: Announcements of individual stocks regarding patent assessments in Japan for the combination of humanized DLK-1 antibody and lenvatinib.
Chiome Bioscience: Change Report
Chiome Bioscience: Announcements of subscription rights (with exercise price adjustment clause) for the 20th and 21st month exercise status
Chiome Bioscience: Initiation of phase I clinical trial of therapeutic antibody drug conjugate ADCT-701.
Chiome Bioscience: Announcements of individual stocks: Start of administration in Phase 1 clinical trials of ADC therapy for cancer treatment ADCT-701.
Chiome Bioscience: Mass Ownership Report
Chiome Bioscience: Announcements of individual stocks regarding completion of acquisition and cancellation of the 20th subscription rights, 21st subscription rights (with exercise price adjustment clause), 22nd subscription rights, and payment completion related to the issuance of the first unsecured bonds.
Chiome Bioscience: Supplementary explanation for fundraising.
Chiome Bioscience: Announcements of individual stocks regarding the acquisition and cancellation of the 20th subscription rights, the 21st subscription rights with exercise price adjustment provisions, the 22nd subscription rights, and the issuance of the 1st unsecured corporate bonds.
Chiome Bioscience: Securities registration statement (embedding method)
Chiome Bioscience: Announcements of individual stock: Business partnership about the development of biosimilar pharmaceuticals with KidsWell Bio Co., Ltd.
Chiome Bioscience: Notice regarding the monthly exercise status of the 20th Stock Acquisition Rights (with exercise price amendment clause)
Analysis
Price Target
No Data
